Showing results (151-160 of 202) with videos related to
Sort By:
Pageof 21
American Heart Journal|July 29, 2014
Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trialErik Kjøller, Jørgen Hilden, Per Winkel, et al.Danish Medical Journal|March 3, 2026
Effect of clarithromycin versus placebo on risk of atrial fibrillationGorm Boje Jensen, Markus Harboe Olsen, Magnus Thorsten Jensen, et al.BMJ Open|August 22, 2020
Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trialPer Winkel, Janus Christian Jakobsen, Jørgen Hilden, et al.Diagnostics (Basel, Switzerland)|May 19, 2018
Angiogenesis PET Tracer Uptake (68Ga-NODAGA-E[(cRGDyK)]₂) in Induced Myocardial Infarction and Stromal Cell Treatment in MinipigsThomas Rasmussen, Bjarke Follin, Jens Kastrup, et al.American Heart Journal|February 22, 2003
Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DANSTENT)--a randomized trial comparing a first-generation stent with a second-generation stentErik Jørgensen, Henning Kelbaek, Steffen Helqvist, et al.European Journal of Heart Failure|February 22, 2019
Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)Christina Paitazoglou, Martin W Bergmann, Bojan Vrtovec, et al.ESC Heart Failure|January 19, 2022
Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trialAnthony Mathur, Doo Sun Sim, Fizzah Choudry, et al.Journal of Cardiovascular Translational Research|March 2, 2021
Proteoglycan Remodeling Is Accelerated in Females with Angina Pectoris and Diffuse Myocardial Fibrosis: the iPOWER StudyNaja Dam Mygind, Signe Holm Nielsen, Marie Mide Michelsen, et al.Atherosclerosis|September 28, 2018
Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-studyJonas Wuopio, Jørgen Hilden, Carl Bring, et al.Journal of the American Heart Association|April 25, 2018
10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial SubstudyAxel C Carlsson, Toralph Ruge, Erik Kjøller, et al.Pageof 21